Yeleswaram Krishnaswamy sold $20K of RAPP
Yeleswaram Krishnaswamy (Chief Development Officer) sold 404 shares of Rapport Therapeutics, Inc. (RAPP) at $49.90 on 2026-08-19 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
Provides fresh, primary‑source data on insider activity for RAPP.
Market read
Insider sale of modest size; may cause slight short‑term price pressure.
What to watch
Pre‑arranged 10b5‑1 plan may mask timing motives; overall ownership remains substantial.
Background
SEC Form 4 filing discloses insider transactions required by regulation.
Ticker impact
Chief Development Officer sold 404 shares for $20,159 via a 10b5-1 plan, reducing his stake to 246,022 shares.
Potential modest dip in short-term price as market digests the sell.
Small sale size relative to holdings, but executed under a pre-arranged plan, limits strong inference.
Market effects
Minimal impact on biotech sector; typical insider sale.
No broader regional effect.
Limited to investors tracking Rapport Therapeutics.
Counterpoint
The sale could be routine liquidity management, not a negative signal.
Key entities
- personYeleswaram Krishnaswamy
Chief Development Officer of Rapport Therapeutics, insider seller.
- companyRapport Therapeutics, Inc.
Biotech firm listed on NASDAQ under ticker RAPP.